A UK health board has rejected Eisai’s Halaven (eribulin) for the treatment of advanced metastatic breast cancer.
In a draft guidance issued for public consultation, the National Institute for Health and Clinical Excellence (NICE) said that although the drug could potentially help patients live a little longer, it also caused more negative side effects than other treatments.
NICE chief executive Andrew Dillon said: “The majority of the evidence on the effectiveness of eribulin submitted by the manufacturer was based on one study that compared eribulin to a ‘treatment of physician’s choice’.
“The manufacturer and other stakeholders now have an opportunity to comment on the preliminary recommendations which are available for public consultation. Comments received during this consultation will be fully considered by the Committee and following this meeting the next draft guidance will be issued.”
Eisai has agreed a patient access scheme with the Department of Health which makes eribulin available at a discounted price.
The estimated cost for each quality-adjusted year of life gained through eribulin, compared with the ‘treatment of physician’s choice’, is thought to be in excess of £68,600.